| Pharmaceutical Information |
| Drug Name |
Gatifloxacin |
| Drug ID |
BADD_D01006 |
| Description |
Gatifloxacin is an antibiotic agent and a member of the fourth-generation fluoroquinolone family. It works by inhibiting the bacterial enzymes DNA gyrase and topoisomerase IV. It was first introduced by Bristol-Myers Squibb in 1999 under the brand name Tequin® for the treatment of respiratory tract infections. Gatifloxacin is available as tablets and in various aqueous solutions for intravenous therapy. It is also available as eye drops under the brand name Zymar® marketed by Allergan. |
| Indications and Usage |
For the treatment of bronchitis, sinusitis, community-acquired pneumonia, and skin infections (abscesses, wounds) caused by S. pneumoniae, H. influenzae, S. aureus, M. pneumoniae, C. pneumoniae, L. pneumophila, S. pyogenes |
| Marketing Status |
approved; investigational |
| ATC Code |
J01MA16; S01AE06 |
| DrugBank ID |
DB01044
|
| KEGG ID |
D00589; D08011
|
| MeSH ID |
D000077734
|
| PubChem ID |
5379
|
| TTD Drug ID |
D03CQE
|
| NDC Product Code |
53476-1155; 50383-189; 68180-435; 60758-615; 61314-672; 0023-3615 |
| UNII |
L4618BD7KJ
|
| Synonyms |
Gatifloxacin | 1-cyclopropyl-1,4-dihydro-6-fluoro-8-methoxy-7-(3-methyl-1-piperazinyl)-4-oxo-3-quinolinecarboxylic acid | Gatifloxacine | Tequin | AM 1155 | AM-1155 | CG 5501 | BMS-206584 | BMS 206584 | BMS206584 | Zymar |
|
| Chemical Information |
| Molecular Formula |
C19H22FN3O4 |
| CAS Registry Number |
112811-59-3 |
| SMILES |
CC1CN(CCN1)C2=C(C=C3C(=C2OC)N(C=C(C3=O)C(=O)O)C4CC4)F |
| Chemical Structure |
|
|
| ADRs Induced by Drug |
|
|
*The priority for ADR severity classification is based on FAERS assessment, followed by the most severe level in CTCAE rating. If neither is available, it will be displayed as 'Not available'.
**The 'Not Available' level is hidden by default and can be restored by clicking on the legend twice..
|
|
|
